Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ARVN

Arvinas Inc

Feb 14 • 12:23PM ET

17.50

Dollar change -0.17
Percentage change -0.94	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX IONS EXEL NBIX GILD BMRN REGN ALNY SRPT BIIB

| Held by: VTI IWM VB VXF VBK IWO IBB VTWO SCHA VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.08	Insider Own	13.37%	Shs Outstand	68.80M	Perf Week	-6.40%
Market Cap	1.20B	Forward P/E	-	EPS next Y	-3.98	Insider Trans	-0.01%	Shs Float	59.58M	Perf Month	-1.28%
Income	-149.70M	PEG	-	EPS next Q	-1.02	Inst Own	100.68%	Short Float	17.52%	Perf Quarter	-33.47%
Sales	161.00M	P/S	7.48	EPS this Y	-41.50%	Inst Trans	2.87%	Short Ratio	11.44	Perf Half Y	-26.49%
Book/sh	8.16	P/B	2.14	EPS next Y	-1.67%	ROA	-27.37%	Short Interest	10.44M	Perf Year	-63.36%
Cash/sh	15.11	P/C	1.16	EPS next 5Y	-2.48%	ROE	-60.80%	52W Range	16.61 - 53.08	Perf YTD	-8.70%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-5.32%	ROI	-26.28%	52W High	-67.03%	Beta	1.97
Dividend TTM	-	Quick Ratio	4.64	Sales past 5Y	87.40%	Gross Margin	100.00%	52W Low	5.38%	ATR (14)	1.23
Dividend Ex-Date	-	Current Ratio	4.64	EPS Y/Y TTM	7.38%	Oper. Margin	-230.43%	RSI (14)	42.61	Volatility	8.06% 6.41%
Employees	430	Debt/Eq	0.02	Sales Y/Y TTM	105.10%	Profit Margin	-92.98%	Recom	1.05	Target Price	63.22
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	75.31%	Payout	-	Rel Volume	0.65	Prev Close	17.67
Sales Surprise	-4.52%	EPS Surprise	34.07%	Sales Q/Q	237.35%	Earnings	Feb 11 BMO	Avg Volume	912.57K	Price	17.50
SMA20	-3.42%	SMA50	-9.58%	SMA200	-30.49%	Trades		Volume	280,913	Change	-0.94%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-24	Initiated	BTIG Research	Buy	$69
Nov-18-24	Initiated	Stephens	Overweight	$55
Feb-28-24	Reiterated	Oppenheimer	Outperform	$95 → $80
Feb-14-24	Downgrade	Citigroup	Buy → Neutral	$36 → $55
Feb-01-24	Initiated	Goldman	Buy	$70
Dec-19-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$25 → $63
Dec-06-23	Upgrade	Jefferies	Hold → Buy	$40
Nov-20-23	Upgrade	Guggenheim	Neutral → Buy
Oct-23-23	Upgrade	Wedbush	Neutral → Outperform	$27 → $24
Jun-26-23	Resumed	Oppenheimer	Outperform	$95
Jan-12-23	Downgrade	Guggenheim	Buy → Neutral
Jan-03-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$83 → $49
Sep-09-22	Initiated	Barclays	Overweight	$90
Jun-21-22	Initiated	Jefferies	Hold	$42
May-09-22	Downgrade	Wedbush	Outperform → Neutral
Apr-28-22	Initiated	Credit Suisse	Outperform	$104
Apr-06-22	Initiated	Morgan Stanley	Equal-Weight	$65
Feb-11-22	Resumed	BMO Capital Markets	Outperform	$125
Feb-10-22	Initiated	Wells Fargo	Overweight	$98
Jan-19-22	Initiated	Goldman	Buy	$157

Show Previous Ratings

Today 09:55AM	How Much Upside is Left in Arvinas (ARVN)? Wall Street Analysts Think 235.09% (Zacks)
Feb-12-25 02:49AM	Q4 2024 Arvinas Inc Earnings Call (Thomson Reuters StreetEvents)
02:06AM	Arvinas Inc (ARVN) Q4 2024 Earnings Call Highlights: Strong Financial Position and Promising ... (GuruFocus.com)
Feb-11-25 08:15AM	Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -6.80%
07:00AM	Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
07:17AM	Loading…
Feb-10-25 07:17AM	What To Expect From Arvinas Inc (ARVN) Q4 2024 Earnings (GuruFocus.com)
Feb-03-25 07:00AM	Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025 (GlobeNewswire)
Jan-21-25 04:29AM	2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025 (Motley Fool)
Jan-10-25 07:00AM	Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update (GlobeNewswire) -6.05%
Dec-11-24 05:38AM	Arvinas and Pfizers combo therapy shows promise in breast cancer trial (Clinical Trials Arena) -8.34%
Dec-10-24 01:23PM	Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients (Benzinga)
09:05AM	Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-04-24 01:19PM	Why Is Arvinas, Inc. (ARVN) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Nov-27-24 07:00AM	Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) +6.13%
Nov-25-24 05:35PM	Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire)
09:06AM	Loading…
Nov-19-24 09:06AM	Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode (Insider Monkey) -6.68%
Nov-04-24 07:00AM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-31-24 03:05AM	Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ... (GuruFocus.com)
Oct-30-24 08:10AM	Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-29-24 09:10AM	Arvinas Inc (ARVN) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-23-24 08:44AM	Arvinas (ARVN): A Small-Cap Biotech with High Growth Potential (Insider Monkey)
Oct-22-24 04:05PM	Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day (GlobeNewswire)
Oct-21-24 07:00AM	Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024 (GlobeNewswire)
Sep-12-24 01:18AM	Vanguard Group Inc's Strategic Acquisition of Arvinas Inc Shares (GuruFocus.com)
Sep-05-24 12:01AM	Arvinas, Inc. (ARVN): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 07:00AM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-30-24 01:53PM	ARVN Stock Earnings: Arvinas Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
08:20AM	Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Loading…
07:00AM	Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-22-24 08:30AM	HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200 (GlobeNewswire)
Jul-17-24 03:06PM	Biotech Arvinas Stock Earns 82 RS Rating (Investor's Business Daily)
08:44AM	Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains? (Zacks)
Jul-15-24 08:00AM	Milestone Pharmaceuticals Refreshes Board of Directors (GlobeNewswire)
Jun-27-24 09:31AM	Arvinas, Inc. (ARVN): Why Did Analysts Give This Small-Cap Stock a Strong Buy Rating? (Insider Monkey)
Jun-26-24 04:36PM	Top 10 Small-Cap Stocks with Highest Upside Potential (Insider Monkey) +5.76%
Jun-24-24 04:37PM	Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer (GlobeNewswire)
Jun-21-24 07:00AM	Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2 (GlobeNewswire)
Jun-17-24 07:00AM	Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer (GlobeNewswire)
Jun-03-24 04:30PM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire) -15.84%
May-23-24 05:00PM	Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress (GlobeNewswire)
May-16-24 09:10AM	Sector Update: Health Care Stocks Steady Premarket Thursday (MT Newswires)
08:07AM	Correction: Arvinas, Pfizer Breast Cancer Treatment Shows 'Encouraging' Clinical Activity (MT Newswires)
07:01AM	Arvinas, Pfizer Breast Cancer Treatment Shows 'Encouraging' Clinical Activity (MT Newswires)
06:00AM	Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE) (GlobeNewswire)
May-09-24 04:42PM	Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress (GlobeNewswire)
May-08-24 08:36AM	Oppenheimer Adjusts Arvinas Price Target to $70 From $80, Maintains Outperform Rating (MT Newswires) -5.71%
May-07-24 01:54PM	ARVN Stock Earnings: Arvinas Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) +6.42%
10:27AM	Arvinas Shares Up After Q1 Net Loss Narrows (MT Newswires)
08:15AM	Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-02-24 10:00AM	Why Earnings Season Could Be Great for Arvinas (ARVN) (Zacks)
07:00AM	Arvinas to Present at Upcoming Investor Conferences (GlobeNewswire)
May-01-24 12:00PM	Arvinas (ARVN) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Apr-30-24 10:30AM	As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response (PR Newswire)
Apr-26-24 10:00AM	Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-24-24 04:30PM	Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer (GlobeNewswire)
Apr-11-24 04:19PM	Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options (Investor's Business Daily)
12:25PM	Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024 (Associated Press Finance)
09:17AM	Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options (Investor's Business Daily)
08:06AM	Novartis pays $150M for Arvinas' phase 3-ready prostate cancer protein degrader (FierceBiotech.com)
07:40AM	UPDATE 2-Novartis taps Arvinas' cancer drug for up to $1 billion (Reuters)
07:17AM	Novartis licenses Arvinas' cancer drug for up to $1 billion (Reuters)
07:00AM	Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer (GlobeNewswire)
Apr-09-24 08:48AM	Is Arvinas (ARVN) Stock a Solid Choice Right Now? (Zacks)
Mar-18-24 04:40PM	Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire) -5.02%
Mar-04-24 07:00AM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-28-24 08:30AM	Is a Surprise Coming for Arvinas (ARVN) This Earnings Season? (Zacks)
Feb-27-24 08:30AM	Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-23-24 09:55AM	Wall Street Analysts See a 30.21% Upside in Arvinas, Inc. (ARVN): Can the Stock Really Move This High? (Zacks)
Feb-21-24 12:00PM	What Makes Arvinas, Inc. (ARVN) a Strong Momentum Stock: Buy Now? (Zacks) -5.73%
Feb-20-24 04:05PM	Arvinas Announces Chief Financial Officer Transition (GlobeNewswire)
07:00AM	Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease (GlobeNewswire)
Feb-14-24 08:00AM	Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer (GlobeNewswire)
Feb-08-24 08:26AM	Goldman Sachs Predicts at Least 45% Rally for These 2 Strong Buy Stocks Heres Why They Have Solid Upside (TipRanks)
Feb-06-24 09:55AM	Wall Street Analysts Think Arvinas, Inc. (ARVN) Could Surge 26.67%: Read This Before Placing a Bet (Zacks) +5.85%
06:45AM	Arvinas and Pfizer's Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer (GlobeNewswire)
Feb-02-24 02:59AM	Arvinas, Inc. (ARVN) Soars 10.0%: Is Further Upside Left in the Stock? (Zacks)
Feb-01-24 04:30PM	Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference (GlobeNewswire) +10.00%
Jan-17-24 12:00PM	What Makes Arvinas, Inc. (ARVN) a New Strong Buy Stock (Zacks)
Jan-16-24 05:01PM	Arvinas Appoints Jared Freedberg as General Counsel (GlobeNewswire)
Jan-01-24 09:55AM	Arvinas, Inc. (ARVN) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
09:40AM	Is Arvinas (ARVN) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-27-23 05:03AM	TipRanks Perfect 10 List: These 3 Top-Scoring Stocks Are Poised to Perform in 2024 (TipRanks)
Dec-25-23 09:55AM	Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to Trade (Zacks)
Dec-18-23 02:58PM	12 Most Promising Cancer Stocks According to Analysts (Insider Monkey)
Dec-15-23 09:40AM	Has Arvinas (ARVN) Outpaced Other Medical Stocks This Year? (Zacks)
Dec-05-23 10:52PM	Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program (GlobeNewswire) +30.77%
01:33PM	Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE ) and Plans to Expand Vepdegestrant Development Program (GlobeNewswire)
Dec-01-23 09:55AM	Does Arvinas, Inc. (ARVN) Have the Potential to Rally 145.52% as Wall Street Analysts Expect? (Zacks) +7.42%
Nov-28-23 05:05PM	Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-27-23 07:00AM	Arvinas Announces Oversubscribed $350 Million Private Placement (GlobeNewswire) +10.24%
Nov-15-23 09:55AM	Wall Street Analysts Predict a 165.07% Upside in Arvinas, Inc. (ARVN): Here's What You Should Know (Zacks)
Nov-13-23 09:55AM	Arvinas, Inc. (ARVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks) +10.67%
Nov-07-23 08:02AM	Arvinas Inc (ARVN) Reports Q3 2023 Financial Results and Provides Corporate Update (GuruFocus.com) +5.08%
07:00AM	Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-23 07:00AM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-31-23 07:39AM	Strength Seen in Arvinas, Inc. (ARVN): Can Its 6.3% Jump Turn into More Strength? (Zacks) +6.90%

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Loomis David K	Chief Accounting Officer	Nov 07 '24	Sale	27.69	231	6,396	8,040	Nov 12 05:34 PM
Houston John G	President and CEO	Feb 23 '24	Sale	47.05	5,196	244,472	1,036,681	Feb 27 06:35 PM
Cassidy Sean A	Chief Financial Officer	Feb 23 '24	Sale	47.05	1,702	80,079	181,916	Feb 27 06:34 PM
Peck Ronald	Chief Medical Officer	Feb 23 '24	Sale	47.05	1,699	79,938	67,516	Feb 27 06:34 PM
Taylor Ian	Chief Scientific Officer	Feb 23 '24	Sale	47.05	1,701	80,032	147,522	Feb 27 06:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARVN

Arvinas Inc

Upgrade your FINVIZ experience